Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThRiL: Alternating Thalidomide and Lenalidomide plus Rituximab in CLL
NCT01125176Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2012
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, lenalidomide in chronic lymphocytic leukemia (CLL), sponsored by Weill Cornell Medicine. Started Mar 2012; status: completed.
02
Drugs
thalidomidelenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01125176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125176.